Image Place holder

Kendra Sweet, MD


Specialty: Medical Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Sweet's clinical interests include myeloid malignancies with a particular focus on acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). She completed her medical education at the Medical College of Virginia – Virginia Commonwealth University. Her Internal Medicine residency was completed at the University of Arizona, and her Hematology and Medical Oncology fellowship training was done at Moffitt Cancer Center/The University of South Florida. She is currently an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center and has an appointment as an Assistant Professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine.

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine

Fellowship:

  • H. Lee Moffitt Cancer Center and Research Institute - Hematology-Oncology

Residency:

  • University of Arizona - Internal Medicine

Medical School:

  • Virginia Commonwealth University School of Medicine - MD
Participating Trials

CLINICAL TRIAL 17865
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Condition: Malignant Hematology
Intervention: SL-401
Open

CLINICAL TRIAL 19136
Randomized Phase II Study To Assess The Role Of Nivolumab As Single Agent To Eliminate Minimal Residual Disease And Maintain Remission In Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable
Open

CLINICAL TRIAL 17929
A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: BI 836858
Open

CLINICAL TRIAL 18390
A Phase 1 Dose Escalation, Multicenter, Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 In Patients With Relapsed or Refractory Hematologic Malignancies
Condition: Malignant Hematology
Intervention: FT-1101
Open

CLINICAL TRIAL 18815
A Phase 2 Study of Tipifarnib in Subjects with Chronic Myelomonocytic Leukemia
Condition: Malignant Hematology
Intervention: Zarnestra (tipifarnib); tipifarnib
Open

CLINICAL TRIAL 18876
A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 alone and in Combination with Cytarabine (Ara-C) in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome with Wild-Type TP53
Condition: Malignant Hematology
Intervention: ALRN-6924; Cytarabine (Cytosine Arabinoside)
Open

CLINICAL TRIAL 18406
A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: AZD1775; Belinostat; MK-1775 (AZD1775); PXD101 (Belinostat)
Open

CLINICAL TRIAL 18772
A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Condition: Malignant Hematology
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab); azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18901
A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line Lower (Low and intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Condition: Malignant Hematology
Intervention: OPN-305; azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18939
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Condition: Malignant Hematology
Intervention: H3B-8800
Open

CLINICAL TRIAL 18382
A Phase 1 Study of KB003 in Patients with Previously Treated Chronic Myelomonocytic Leukemia (CMML)
Condition: Malignant Hematology
Intervention: KB003
Open

CLINICAL TRIAL 18891
A Multinational Open-Label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients with Different Metastatic Tumor Types
Condition: Malignant Hematology
Intervention: NKR-2
Open

CLINICAL TRIAL 18521
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE)Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications
Condition: Gastrointestinal Tumor
Intervention: Abiraterone acetate; Dexamethasone; KPT-8602; Zytiga (Abiraterone acetate)
Open

CLINICAL TRIAL 18950
A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 18599
A Phase 2, International, Multicenter,Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of CC-486 (Oral Azacitidine) Alone and in Combination with Durvalumab (Medi4736) in Subjects with Myelodysplastic Syndromes who Fail to Achieve an Objective Response to Treatment with Azacitidine for Injection or Decitabine
Condition: Malignant Hematology
Intervention: AMP-514 (Durvalumab); Azacitidine (Oral); CC-486 (Azacitidine (Oral)); Durvalumab; MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18973
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Condition: Malignant Hematology
Intervention: APR-246; azacitidine (5-azacitidine)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar;92(3):232-237. Pubmedid: 28006850.
  • Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Aug. Pubmedid: 28869184.
  • Sweet K, Pinilla-Ibarz J. NCCN and ELN: What do the guidelines tell us?. Best Pract Res Clin Haematol. 2016 Sep;29(3):264-270. Pubmedid: 27839567.
  • Sweet K, Pinilla-Ibarz J. Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question. Crit Rev Oncol Hematol. 2016 Jul;103:99-108. Pubmedid: 27262540.
  • Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Ne. 2016 Dec;14(12):1505-1512. Pubmedid: 27956535.
  • Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther. 2016 Aug;9:4937-4957. Pubmedid: 27570458. Pmcid: PMC4986686.
  • Pinilla-Ibarz J, Sweet K, Emole J, Fradley M. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Anticancer Res. 2015 Dec;35(12):6355-6364. Pubmedid: 26637844.
  • Sweet K, Lancet JE. Novel therapeutics in acute myeloid leukemia. Curr Hematol Malig Rep. 2014 Jun;9(2):109-117. Pubmedid: 24633743.
  • Sweet K, Pinilla-Ibarz J, Zhang L. Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations. Patient Prefer Adherence. 2014 Jul;8:981-986. Pubmedid: 25045255. Pmcid: PMC4099191.
  • Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. Int J Hematol. 2014 Dec;100(6):567-574. Pubmedid: 25281405.
  • Sweet K, Zhang L, Pinilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol. 2013 Jul;6:54. Pubmedid: 23870290. Pmcid: PMC3737033.
  • Sweet K, Oehler V. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?. Hematology Am Soc Hematol Educ Program. 2013 Dec;2013:184-188. Pubmedid: 24319180.
  • Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: Combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol. 2013 Dec;88(3):667-679. Pubmedid: 23969231.
  • Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097-1103. Pubmedid: 23179489.